Jorn Gorlach

Part of Novartis AG, Novartis, Inc. is a company based in San Francisco.

Cogenics Icoria, Inc. provides medical research services. The firm offers genomics and proteomics-related research instruments, consumables, data, including databases, software & other research-oriented products. Icoria offers gene expression analysis and other related services. Its tissue informatics software performs tissue analysis for toxicology studies of early-stage drug candidates and other purposes. The firm also provides biomarkers to develop diagnostics and therapies for liver injuries, metabolic conditions & cancer. The company is headquartered in Research Triangle Park, NC.

Parallax Health Sciences, Inc. was an integrated digital healthcare company. It was engaged in the provision of personalized patient care through remote healthcare services, behavioral health systems, and Point-of-Care diagnostic testing. The firm operated through the following segments: Remote Patient Monitoring, Behavioral Health Systems, and Corporate. The Remote Patient Monitoring segment offered a technology platform that includes a complete remote patient care delivery system through PHM. The Behavioral Health Systems segment included the intellectual property, Reliable Evidence-Based Outcomes Optimization Technologies, through its wholly-owned subsidiary, Parallax Behavioral Health, Inc. The Corporate segment consisted of management and administrative services. The company was founded on July 6, 2005 and was headquartered in Los Angeles, CA.

Parallax Diagnostics, Inc. provides diagnostic testing systems and solutions. It develops bio-medical products, diagnostic and monitoring platforms in the area of infectious diseases. The company was founded on April 12, 2010 and is headquartered in Cambridge, MA.

Part of Sarepta Therapeutics, Inc., Ercole Biotech, Inc. develops splice switching drugs for the treatment of major human diseases. The company is based in Research Triangle Park, NC. The company was founded by Jorn Gorlach. Ercole Biotech was acquired by Sarepta Therapeutics, Inc. on March 20, 2008 for $8.25 million.